Logo

ParagonDx Signs on Partner for Warfarin PGx Test

Apr 08, 2008
NEW YORK (GenomeWeb News) – ParagonDx said today that Iverson Genetic Diagnostics will use its pharmacogenomics test to determine warfarin sensitivity among patients taking the blood thinner.
 
IGD is a Seattle-based CLIA-certified lab that had been using a blood-based method for determining warfarin dosing, Research Triangle Park, NC-based ParagonDx said. Now, it will use a saliva-based test that incorporates ParagonDx’s technology and provides results the same day, as opposed to in two to three days with the blood-based test.
 
Terms of the alliance were not disclosed.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.